![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PRDM16 |
Gene summary for PRDM16 |
![]() |
Gene information | Species | Human | Gene symbol | PRDM16 | Gene ID | 63976 |
Gene name | PR/SET domain 16 | |
Gene Alias | CMD1LL | |
Cytomap | 1p36.32 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9HAZ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
63976 | PRDM16 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.53e-04 | 5.65e-01 | 0.3371 |
63976 | PRDM16 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.83e-04 | 6.00e-01 | 0.343 |
63976 | PRDM16 | RNA-P17T-P17T-6 | Human | Lung | IAC | 5.18e-03 | 5.18e-01 | 0.3385 |
63976 | PRDM16 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 4.01e-05 | 3.44e-01 | -0.2116 |
63976 | PRDM16 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 3.10e-02 | 4.09e-01 | -0.1941 |
63976 | PRDM16 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.91e-02 | 2.32e-01 | -0.2119 |
63976 | PRDM16 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 3.40e-02 | 1.84e-01 | -0.0132 |
63976 | PRDM16 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.67e-04 | 2.10e-01 | -0.013 |
63976 | PRDM16 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.14e-02 | 1.93e-01 | -0.0121 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00165704 | Lung | IAC | histone modification | 93/2061 | 463/18723 | 5.41e-09 | 8.03e-07 | 93 |
GO:00715594 | Lung | IAC | response to transforming growth factor beta | 60/2061 | 256/18723 | 9.50e-09 | 1.25e-06 | 60 |
GO:00715604 | Lung | IAC | cellular response to transforming growth factor beta stimulus | 57/2061 | 250/18723 | 6.17e-08 | 6.54e-06 | 57 |
GO:00071794 | Lung | IAC | transforming growth factor beta receptor signaling pathway | 45/2061 | 198/18723 | 1.60e-06 | 7.93e-05 | 45 |
GO:00063256 | Lung | IAC | chromatin organization | 69/2061 | 409/18723 | 2.01e-04 | 3.53e-03 | 69 |
GO:00071785 | Lung | IAC | transmembrane receptor protein serine/threonine kinase signaling pathway | 60/2061 | 355/18723 | 4.82e-04 | 7.03e-03 | 60 |
GO:00454443 | Lung | IAC | fat cell differentiation | 42/2061 | 229/18723 | 6.19e-04 | 8.50e-03 | 42 |
GO:00349684 | Lung | IAC | histone lysine methylation | 25/2061 | 115/18723 | 6.35e-04 | 8.68e-03 | 25 |
GO:00182053 | Lung | IAC | peptidyl-lysine modification | 62/2061 | 376/18723 | 7.55e-04 | 9.82e-03 | 62 |
GO:00180223 | Lung | IAC | peptidyl-lysine methylation | 27/2061 | 131/18723 | 9.41e-04 | 1.14e-02 | 27 |
GO:19038444 | Lung | IAC | regulation of cellular response to transforming growth factor beta stimulus | 27/2061 | 131/18723 | 9.41e-04 | 1.14e-02 | 27 |
GO:00064794 | Lung | IAC | protein methylation | 34/2061 | 181/18723 | 1.28e-03 | 1.45e-02 | 34 |
GO:00082134 | Lung | IAC | protein alkylation | 34/2061 | 181/18723 | 1.28e-03 | 1.45e-02 | 34 |
GO:00165714 | Lung | IAC | histone methylation | 28/2061 | 141/18723 | 1.39e-03 | 1.53e-02 | 28 |
GO:00170153 | Lung | IAC | regulation of transforming growth factor beta receptor signaling pathway | 26/2061 | 128/18723 | 1.45e-03 | 1.55e-02 | 26 |
GO:0030512 | Lung | IAC | negative regulation of transforming growth factor beta receptor signaling pathway | 18/2061 | 81/18723 | 2.68e-03 | 2.46e-02 | 18 |
GO:0061647 | Lung | IAC | histone H3-K9 modification | 12/2061 | 48/18723 | 4.87e-03 | 3.77e-02 | 12 |
GO:00515671 | Lung | IAC | histone H3-K9 methylation | 10/2061 | 37/18723 | 5.45e-03 | 4.08e-02 | 10 |
GO:001657012 | Lung | AIS | histone modification | 81/1849 | 463/18723 | 2.30e-07 | 2.16e-05 | 81 |
GO:007155912 | Lung | AIS | response to transforming growth factor beta | 51/1849 | 256/18723 | 8.45e-07 | 6.08e-05 | 51 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0471416 | Lung | IAC | Thermogenesis | 46/1053 | 232/8465 | 7.85e-04 | 6.38e-03 | 4.23e-03 | 46 |
hsa003109 | Lung | IAC | Lysine degradation | 17/1053 | 63/8465 | 1.35e-03 | 8.63e-03 | 5.73e-03 | 17 |
hsa0471417 | Lung | IAC | Thermogenesis | 46/1053 | 232/8465 | 7.85e-04 | 6.38e-03 | 4.23e-03 | 46 |
hsa0031012 | Lung | IAC | Lysine degradation | 17/1053 | 63/8465 | 1.35e-03 | 8.63e-03 | 5.73e-03 | 17 |
hsa0471423 | Lung | AIS | Thermogenesis | 43/961 | 232/8465 | 7.36e-04 | 6.28e-03 | 4.02e-03 | 43 |
hsa0031022 | Lung | AIS | Lysine degradation | 16/961 | 63/8465 | 1.41e-03 | 9.49e-03 | 6.07e-03 | 16 |
hsa0471433 | Lung | AIS | Thermogenesis | 43/961 | 232/8465 | 7.36e-04 | 6.28e-03 | 4.02e-03 | 43 |
hsa0031032 | Lung | AIS | Lysine degradation | 16/961 | 63/8465 | 1.41e-03 | 9.49e-03 | 6.07e-03 | 16 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRDM16 | SNV | Missense_Mutation | novel | c.689T>C | p.Phe230Ser | p.F230S | Q9HAZ2 | protein_coding | deleterious(0.01) | possibly_damaging(0.892) | TCGA-44-3919-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRDM16 | SNV | Missense_Mutation | c.366N>T | p.Lys122Asn | p.K122N | Q9HAZ2 | protein_coding | tolerated(0.09) | benign(0.007) | TCGA-55-5899-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | CR | |
PRDM16 | SNV | Missense_Mutation | novel | c.1969G>T | p.Gly657Trp | p.G657W | Q9HAZ2 | protein_coding | deleterious(0) | possibly_damaging(0.715) | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PRDM16 | SNV | Missense_Mutation | c.3307N>T | p.Gly1103Cys | p.G1103C | Q9HAZ2 | protein_coding | deleterious(0) | possibly_damaging(0.698) | TCGA-55-7994-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR | |
PRDM16 | SNV | Missense_Mutation | c.2839G>C | p.Gly947Arg | p.G947R | Q9HAZ2 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-55-A492-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRDM16 | SNV | Missense_Mutation | c.2224N>T | p.Asp742Tyr | p.D742Y | Q9HAZ2 | protein_coding | deleterious(0) | possibly_damaging(0.781) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRDM16 | SNV | Missense_Mutation | c.3052G>T | p.Gly1018Trp | p.G1018W | Q9HAZ2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-78-7540-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRDM16 | SNV | Missense_Mutation | c.852N>T | p.Lys284Asn | p.K284N | Q9HAZ2 | protein_coding | deleterious(0.01) | possibly_damaging(0.543) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PRDM16 | SNV | Missense_Mutation | novel | c.1846G>T | p.Asp616Tyr | p.D616Y | Q9HAZ2 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-86-8279-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR |
PRDM16 | SNV | Missense_Mutation | c.1187N>T | p.Cys396Phe | p.C396F | Q9HAZ2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |